Abstract

spp. has been linked to gastrointestinal symptoms, yet its pathogenicity remains uncertain. In addition, the roles of virulence factors, pathogenic potential, and host-specific traits associated with symptomatic infections are still not well understood. The growing number of immunocompromised patients has contributed to an increasing prevalence of spp. infections, which may be implicated in the development of various inflammatory diseases, including irritable bowel syndrome (IBS), colorectal cancer, and autoimmune disorders such as Hashimoto's disease and ulcerative colitis. However, the presence of nonspecific symptoms often complicates diagnosis. This study aimed to present current data on the impact of spp. on the development and progression of gastrointestinal and autoimmune diseases, as well as to explore potential treatment options for spp. infections. A literature review was conducted to analyze the role of spp. in the pathogenesis of specific diseases and to investigate potential mechanisms of its interaction with the host organism. Advances in diagnostic techniques, particularly PCR, allow not only for the detection of spp. but also for the identification of specific subtypes, improving treatment precision. Beyond conventional therapies like metronidazole, there is a growing emphasis on alternative treatments, including the use of medicinal plants and probiotics.

MeSH

Metronidazole, Signs And Symptoms, Probiotics, Autoimmune Diseases, Plants, Medicinal, Therapeutics, Infections

Cited by

• Insights into the Association Between Blastocystis Infection and Colorectal Cancer. Acta Parasitol, 2025
• Assessment of immunological and hematological parameters in Blastocystis species-infected chronic leukemic patients. Gut Pathog, 2025
• Murine Models of Obesity-Related Cancer Risk. Cancer Prev Res (Phila), 2025